TABLE 2.
Recommended oseltamivir regimens for prevention and treatment of adult patients with renal impairment (Tamiflu® Product Monograph, 2014)
| Creatinine clearance | Treatment for five days | Prophylaxis (10–14 days) |
|---|---|---|
| >60 mL/min | 75 mg twice daily | 75 mg once daily |
| >30–60 mL/min | 30 mg suspension twice daily OR 30 mg capsule twice daily | 30 mg once daily |
| 10–30 mL/min | 30 mg once daily | 30 mg on alternate days |
| <10 mL/min (renal failure) | Single 75 mg dose for the duration of illness | No data |
| Dialysis patients | Low-flux HD: 30 mg after each dialysis session | 30 mg after alternate dialysis sessions |
| High-flux HD: 75 mg after each dialysis session | No data | |
| CAPD dialysis: 30 mg once weekly | 30 mg once weekly | |
| CRRT high-flux dialysis: 30 mg daily or 75 mg every second day | No data |
The following dosing regimen has been suggested for children based on limited data: In children >1 year of age, after alternate hemodialysis (HD) sessions (7.5 mg for children weighing >15 kg: 10 mg for children weighing 16–23 kg; 15 mg for children weighing 24–40 kg, and 30 mg for children weighing > 40 kg). While this may provide a framework for guidance, it is strongly suggested that an infectious disease physician, a specialist in renal insufficiency or clinical pharmacist be consulted